ACADIA PHARMACEUTICALS INC — Director's Dealing 2022

May 3, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACADIA PHARMACEUTICALS INC (ACAD)
CIK: 0001070494
Period of Report: 2022-04-29

Reporting Person: DAVIS STEPHEN (Director, CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-04-29	Common Stock	M	15625	—	Acquired	81358	Direct
2022-05-02	Common Stock	S	5483	$18.1819	Disposed	75875	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-04-29	Restricted Stock Units	$	M	15625	Disposed		Common Stock (15625)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock.

F2: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.18 to $18.4025, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon
request, full information regarding the number of shares sold at each separate price within the range set forth above.

F4: The restricted stock units vest in four equal annual installments beginning April 29, 2020.